Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor

European Journal of Pharmacology

Volumn 659, Issue 1, 2011, Pages 30-36

  Quesada, Arnulfo ^a,b   Bui, Peter H ^b   Homanics, Gregg E ^c   Hankinson, Oliver ^b   Handforth, Adrian ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Anti tremor drug; Essential tremor; Harmaline; Mibefradil; NNC 55 0396; T type calcium channel

Indexed keywords

2 [2 [N [(3 BENZIMIDAZOL 2 YL)PROPYL] N METHYLAMINO]ETHYL] 6 FLUORO 1,2,3,4 TETRAHYDRO 1 ISOPROPYL 2 NAPHTHYL CYCLOPROPANECARBOXYLATE DIHYDROCHLORIDE; 4 AMINOBUTYRIC ACID A RECEPTOR; CYTOCHROME P450; HARMALINE; MIBEFRADIL; NNC 55 0396; TESTOSTERONE; UNCLASSIFIED DRUG; (1S,2S)-2-(2-(N-((3-BENZIMIDAZOL-2-YL)PROPYL)-N-METHYLAMINO)ETHYL)-6-FLUORO-1,2,3,4-TETRAHYDRO-1-ISOPROPYL-2-NAPHTYL CYCLOPROPANECARBOXYLATE DIHYDROCHLORIDE; BENZIMIDAZOLE DERIVATIVE; CYCLOPROPANE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR TOXICITY; CONTROLLED STUDY; DEMETHYLATION; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ESSENTIAL TREMOR; HYDROXYLATION; LIVER MICROSOME; MALE; MOTOR PERFORMANCE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SEDATION; WILD TYPE; ANIMAL; ANIMAL BEHAVIOR; CHEMISTRY; COMPARATIVE STUDY; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENE DELETION; GENETICS; METABOLISM; METHYLATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BEHAVIOR, ANIMAL; BENZIMIDAZOLES; CYCLOPROPANES; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; ESSENTIAL TREMOR; GENE DELETION; HARMALINE; HYDROXYLATION; METHYLATION; MIBEFRADIL; MICE; NAPHTHALENES; RECEPTORS, GABA-A; STRUCTURE-ACTIVITY RELATIONSHIP; TESTOSTERONE;

EID: 79958865974     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.01.004     Document Type: Article

References (40)

1. Axelrad, J.E., Louis, E.D., Honig, L.S., Flores, I., Ross, G.W., Pahwa, R., Lyons, K.E., Faust, P.L., Vonsattel, J.P., 2008. Reduced Purkinje cell number in essential tremor: a postmortem study. Arch. Neurol. 65, 101-107.
2. Bernard, J.F., Buisseret-Delmas, C., Compoint, C., Laplante, S., 1984. Harmaline induced tremor. III. A combined simple units, horseradish peroxidase, and 2-deoxyglucose study of the olivocerebellar system in the rat. Exp. Brain Res. 57, 128-137.
3. Bui, P.H., Quesada, A., Handforth, A., Hankinson, O., 2008. The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil. Drug Metab. Dispos. 36, 1291-1299.
4. Chiu, C.S., Brickley, S., Jensen, K., Southwell, A., Mckinney, S., Cull-Candy, S., Mody, I., Lester, H.A., 2005. GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum. J. Neurosci. 25, 3234-3245. (Pubitemid 40463559)
5. Deng, H., Xie, W.J., Le, W.D., Huang, M.S., Jankovic, J., 2006. Genetic analysis of the GABRA1 gene in patients with essential tremor. Neurosci. Lett. 401, 16-19.
6. Dogrul, A., Gardell, L.R., Ossipov, M.H., Tulunay, F.C., Lai, J., Porreca, F., 2003. Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain 105, 159-168. (Pubitemid 37162485)
7. Ernst, M.E., Kelly, M.W., 1998. Mibefradil, a pharmacologically distinct calcium antagonist. Pharmacotherapy 18, 463-485. (Pubitemid 28228330)
8. 2+ channel blocker. Expert Opin. Investig. Drugs 6, 569-582.
9. Handforth, A., Homanics, G.E., Covey, D.F., Krishnan, K., Lee, J.Y., Sakimura, K., Martin, F.C., Quesada, A., 2010. T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor. Neuropharmacology 59, 380-387.
10. Huang, L., Keyser, B.M., Tagmose, T.M., Hansen, J.B., Taylor, J.T., Zhuang, H., Zhang, M., Ragsdale, D.S., Li, M., 2004. NNC 55-0396 [(1S, 2S)-2-(2-(N-[(3-benzimidazol-2-yl) propyl]-N-methylamino)ethyl)-6-fluoro-1, 2, 3, 4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J. Pharmacol. Exp. Ther. 309, 193-199.
11. Köster, B., Deuschl, G., Lauk, M., Timmer, J., Guschlbauer, B., Lücking, C.H., 2002. Essential tremor and cerebellar dysfunction: abnormal ballistic movements. J. Neurol. Neurosurg. Psychiatry 73, 400-405.
12. A receptor α1 subunit knockout mice. J. Clin. Invest. 115, 774-779.
13. Kronenbuerger, M., Gerwig, M., Brol, B., Block, F., Timmann, D., 2007. Eyeblink conditioning is impaired in subjects with essential tremor. Brain 130, 1538-1551. (Pubitemid 47355927)
14. Li, M., Hansen, J.B., Huang, L., Keyser, B.M., Taylor, J.T., 2005. Towards selective antagonists of T-type calcium channels: design, characterization and potential applications of NNC 55-0396. Cardiovasc. Drug Rev. 23, 173-196.
15. Llinás, R., Yarom, Y., 1981. Electrophysiology of mammalian inferior olivary neurones in vitro. Different types of voltage-dependent ionic conductances. J. Physiol. 315, 549-567.
16. Lory, P., Chemin, J., 2007. Towards the discovery of novel T-type calcium channel blockers. Expert Opin. Ther. Targets 11, 717-722.
17. Louis, E.D., Shungu, D.C., Chan, S., Mao, X., Jurewicz, E.C., Watner, D., 2002. Metabolic abnormality in the cerebellum in patients with essential tremor: a proton magnetic resonance spectroscopic imaging study. Neurosci. Lett. 333, 17-20.
18. Martignoni, M., Groothuis, G., de Kanter, R., 2006. Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine. Drug Metab. Dispos. 34, 1047-1054.
19. Martin, F.C., Thu Le, A., Handforth, A., 2005. Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications. Mov. Disord. 20, 298-305.
20. Masubuchi, Y., Iwasa, T., Hosokawa, S., Suzuki, T., Horie, T., Imaoka, S., Funae, Y., Narimatsu, S., 1997. Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes. J. Pharmacol. Exp. Ther. 282, 1435-1441.
21. Molineux, M.L., McRory, J.E., McKay, B.E., Hamid, J., Mehaffey, W.H., Rehak, R., Snutch, T.P., Zamponi, G.W., Turner, R.W., 2006. Specific T-type calcium channel isoforms are associated with distinct burst phenotypes in deep cerebellar nuclear neurons. Proc. Natl Acad. Sci. USA 103, 5555-5560.
22. Moosmang, S., Haider, N., Brüderl, B., Welling, A., Hofmann, F., 2006. Antihypertensive effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel Cav1.2. Circ. Res. 98, 105-110.
23. Nebert, D.W., 1997. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am. J. Hum. Genet. 60, 265-271.
24. A receptor regulates inhibitory synaptic strength. J. Neurophysiol. 92, 1718-1727.
25. A receptor current: a role for GABA uptake transporters. J. Neurosci. 26, 9323-9331.
26. Po, A.L., Zhang, W.Y., 1998. What lessons can be learnt from withdrawal of mibefradil from the market? Lancet 351, 1829-1830.
27. Pranzatelli, M.R., Snodgrass, S.R., 1987. Harmala alkaloids and related β-carbolines: a myoclonic model and antimyoclonic drugs. Exp. Neurol. 96, 703-719.
28. Sango, K., McDonald, M.P., Crawley, J.N., Mack, M.L., Tifft, C.J., Skop, E., Starr, C.M., Hoffmann, A., Sandhoff, K., Suzuki, K., Proia, R.L., 1996. Mice lacking both subunits of lysosomal β-hexosaminidase display gangliosidosis and mucopolysaccharidosis. Nat. Genet. 14, 348-352.
29. Shipe, W.D., Barrow, J.C., Yang, Z.Q., Lindsley, C.W., Yang, F.V., Schlegel, K.A., Shu, Y., Rittle, K.E., Bock, M.G., Hartman, G.D., Tang, C., Ballard, J.E., Kuo, Y., Adarayan, E.D., Prueksaritanont, T., Zrada, M.M., Uebele, V.N., Nuss, C.E., Connolly, T.M., Doran, S.M., Fox, S.V., Kraus, R.L., Marino, M.J., Graufelds, V.K., Vargas, H.M., Bunting, P.B., Hasbun-Manning, M., Evans, R.M., Koblan, K.S., Renger, J.J., 2008. Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist. J. Med. Chem. 51, 3692-3695.
30. Stöhr, T., Lekieffre, D., Freitag, J., 2008. Lacosamide, the new anticonvulsant, effectively reduces harmaline-induced tremors in rats. Eur. J. Pharmacol. 589, 114-116.
31. Stolze, H., Petersen, G., Raethjen, J., Wenzelburger, R., Deuschl, G., 2001. The gait disorder of advanced essential tremor. Brain 124, 2278-2286. (Pubitemid 33055371)
32. Todorovic, S.M., Meyenburg, A., Jevtovic-Todorovic, V., 2002. Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker. Brain Res. 951, 336-340. (Pubitemid 35248032)
33. A receptor: differential interaction of benzodiazepines and neuroactive steroids with ethanol. Psychopharmacology (Berl) 141, 77-82.
34. Vicini, S., Ferguson, C., Prybylowski, K., Kralic, J., Morrow, A.L., Homanics, G.E., 2001. GABAA receptor α1 subunit deletion prevents developmental changes of inhibitory synaptic currents in cerebellar neurons. J. Neurosci. 21, 3009-3016. (Pubitemid 32323482)
35. Wandel, C., Kim, R.B., Guengerich, F.P., Wood, A.J., 2000. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab. Dispos. 28, 895-898.
36. Welker, H.A., Wiltshire, H., Bullingham, R., 1998. Clinical pharmacokinetics of mibefradil. Clin. Pharmacokinet. 35, 405-423.
37. 2+ currents in pancreatic β-cells. J. Pharmacol. Exp. Ther. 292, 939-943.
38. Yang, Z.Q., Barrow, J.C., Shipe, W.D., Schlegel, K.A., Shu, Y., Yang, F.V., Lindsley, C.W., Rittle, K.E., Bock, M.G., Hartman, G.D., Uebele, V.N., Nuss, C.E., Fox, S.V., Kraus, R.L., Doran, S.M., Connolly, T.M., Tang, C., Ballard, J.E., Kuo, Y., Adarayan, E.D., Prueksaritanont, T., Zrada, M.M., Marino, M.J., Graufelds, V.K., DiLella, A.G., Reynolds, I.J., Vargas, H.M., Bunting, P.B., Woltmann, R.F., Magee, M.M., Koblan, K.S., Renger, J.J., 2008. Discovery of 1, 4-substituted piperidines as potent and selective inhibitors of T-type calcium channels. J. Med. Chem. 51, 6471-6477.
39. Yu, A.M., Idle, J.R., Krausz, K.W., Küpfer, A., Gonzalez, F.J., 2003. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic β-carboline alkaloids harmaline and harmine. J. Pharmacol. Exp. Ther. 305, 315-322.
40. Zesiewicz, T.A., Sullivan, K.L., Ward, C.L., Hauser, R.A., 2007. Tiagabine and exacerbation of essential tremor. Mov. Disord. 22, 2132-2133.